Stories about Study

Subscribe to Study

13.11.2020 – 18:00

FDI World Dental Federation

Study shows dramatic rise in antibiotics prescribed to dental patients in England during COVID-19 lockdown earlier this year

more
29.09.2020 – 09:30

Medasense Biometrics Ltd
New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery

Ramat Gan, Israel (ots/PRNewswire) - A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that ...

more
02.09.2020 – 11:30

Institute for Advanced Sustainability Studies e.V. (IASS)
Study: Creating a global standard for sustainability reporting

PRESS RELEASE Study Creating a global standard for sustainability reporting For customers, investors and consumers alike, it can make a difference whether a company operates sustainably and adheres to ethical and ecological standards. Standardized and verifiable reports are needed so that companies can provide credible and ...
This article online

more
13.03.2020 – 10:27

INFOSYS
Key Workplace Transformation Decisions Shifting From CHROs to CEOs: Infosys Study

Bengaluru, India (ots/PRNewswire) - - Enhanced productivity and delivering superior customer experience are primary triggers for adoption of workplace transformation - Choosing the right solutions, data security, and organizational buy-in are key concerns - Digital transformation tops the workplace modernization agenda for organizations Infosys Knowledge Institute ...

more
18.12.2019 – 09:00

Daiichi Sankyo Europe GmbH
Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy, showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial[1] · Study reports LIXIANA outcomes from one of the largest observational studies in mainly Caucasian AF ...

more
09.08.2019 – 16:37

Technische Universität München
Employees less upset at being replaced by robots than by other people

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35645/ NEWS RELEASE Employees less upset at being replaced by robots than by other people Study assesses psychological impact of job losses through ...

more
05.06.2019 – 07:30

creditshelf
Study of SMEs: Return-Turbo Digitization - Outperformers rely on IoT, AI and Co.

Frankfurt (ots) - For 37 percent of medium-sized companies with above-average returns, topics such as the Internet of Things or artificial intelligence are very important in ongoing investment planning. By comparison, only 18 percent of companies with an average or below-average return put these topics at the top of their agenda. These are the results of the ...

more
06.11.2018 – 14:47

IFCO Systems
Study: IFCO RPCs extend shelf life of fresh produce by up to 4 days

Pullach, Germany (ots) - IFCO, the leading global provider of reusable packaging solutions for fresh foods, announced today the results of a study (https://www.ifco.com/000f855f4e852d8f) on the impact of IFCO reusable plastic containers (RPCs) on the shelf life of fresh produce. IFCO RPCs extend the freshness and visual appeal of fresh fruits and vegetables for up to four days compared to single-use packaging. The study ...

more
22.10.2013 – 13:00

Astellas Pharma Europe Limited
Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer

Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...

more

1